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Summary
The mechanism of target cell lysis in cytotoxic lym-
phocyte-mediated death is not well understood, and
the role of granzymes in this process is unclear.
Chemical functional probes were thus prepared for
the major granzymes A and B to deconvolute their
role in natural killer cell-mediated lysis of target cells.
These biotinylated and substrate specificity-based
diphenyl phosphonates allowed facile evaluation of
selectivity through activity-based profiling in cell ly-
sates and intact cells. Both inhibitors were found to
be extremely selective in vitro and in cells. Use of
these inhibitors in cell-based assays revealed gran-
zyme A to be a minor effector and granzyme B to be
a major effector of target cell lysis by natural killer
cells. These studies indicate that the proapoptotic
granzyme B functions also as a pronecrotic effector
of target cell death.
Introduction
Natural killer (NK) cells and cytotoxic T lymphocytes
(CTL) function in immunity as the primary line of de-
fense against viruses and other intracellular pathogens.
These cytotoxic lymphocytes recognize host cells com-
promised by infection and kill them to halt pathogen
proliferation. Death of infected target cells is predomi-
nantly mediated by members of the granzyme family of
serine proteases in conjunction with the pore-forming
protein perforin [1]. Through a mechanism referred to
as granule exocytosis, vesicles containing the gran-
zymes and perforin are secreted from the cytotoxic
lymphocyte, and granule contents are taken up by the
target cell into endocytic vesicles. Perforin then acts as
an endosomolytic agent, allowing escape of the gran-
zymes into the cytoplasm to carry out a series of pro-
teolytic events that lead to several morphologic changes
in the target cell. These include phosphatidylserine ex-
ternalization, DNA damage, mitochondrial damage, and
cell lysis, all of which culminate in death and elimination
of the infected cell [2]. Although an essential compo-
nent of immunity under normal conditions, aberrant
cytotoxic lymphocyte activity can result in disease. In
some cases, the granzymes may thus represent poten-
tial therapeutic targets [3–7].
Granzymes A and B are the most prominent mem-
bers of the granzyme family, as numerous experiments
have implicated them in the induction of target cell
death. Notably, mice lacking either or both of these*Correspondence: craik@cgl.ucsf.edugranzymes exhibit increased susceptibility to viral in-
fections [8]. Additionally, far more is known about the
molecular mechanism of action of these two gran-
zymes than is known about the remaining “orphan” hu-
man granzymes, H, K, and M [9]. The substrate speci-
ficity of granzyme B is similar to that of apical
caspases, and its function as an activator of apoptosis
reflects this similarity. Granzyme B may also induce
death through caspase-independent pathways. Major
hallmarks of granzyme B-induced cellular damage are
oligonucleosomal DNA fragmentation and mitochon-
drial damage [10]. An important pathway to granzyme
A-induced damage involves cleavage and inactivation
of SET (also known as PHAPII, TAF-Iβ, I2PP2A), which
functions as an inhibitor of the DNase activity of the
tumor metastasis suppressor NM23-H1. The resulting
hallmark of granzyme A-induced damage is single-
stranded DNA nicks mediated by NM23-H1 [11].
Most information concerning the function of gran-
zymes A and B has been derived from genetic studies,
or from reconstituted systems in which target cells are
killed by exogenous addition of purified granzymes and
perforin. Although genetic deletions in mice offer a high
level of physiological relevance, compensation by re-
lated genes can sometimes obscure effects [12]. Com-
pensation may be a particularly valid consideration in
the case of the granzymes because several family
members are highly homologous. Use of a reconstitu-
ted system is a practical approach to isolate effects of
a specific granzyme, but it offers limited physiological
relevance and can thus be susceptible to artifacts. A
clear example of the potential discord between results
obtained by using the two approaches comes from
analysis of cell lysis, the standard morphological parame-
ter for measurement of cytotoxic lymphocyte function.
Cytotoxic lymphocytes from mice lacking either gran-
zyme A, granzyme B, or both granzymes exhibit a rela-
tively normal ability to lyse target cells [13]. In contrast,
treatment of target cells with sublytic levels of perforin
and either granzyme A or granzyme B leads to efficient
cell lysis [14, 15].
As a means to study protein function, the use of se-
lective chemical inhibitors can offer a high level of
physiological relevance and a high level of temporal
control that circumvents compensation by related
genes [16]. Such an approach thus has the potential to
complement the present understanding of the function
of granzymes A and B. Toward the goal of establishing
chemical functional probes for study of these two major
granzymes, selective inhibitors targeted against gran-
zymes A and B were developed for use in assays of
cytotoxic lymphocyte function. Both inhibitors were de-
signed to have the general architecture of tagged affin-
ity labels. This design allowed for rapid evaluation of
selectivity in the context of NK and target cell pro-
teomes by SDS-PAGE analysis, followed by detection
of a biotin label. Each inhibitor was found to be ex-
tremely selective for its target enzyme in the context of
complex biochemical mixtures. The granzyme A- and
B-targeted inhibitors were thus used to probe the con-
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568etributions of these two major granzymes to target cell
wlysis mediated by NK cells. In contrast to results ob-
[tained by using cytotoxic lymphocytes from granzyme-
gdeficient mice, or reconstituted systems of purified
Vgranzymes and perforin, these studies revealed gran-
bzyme A to be a minor effector and granzyme B to be a
(major effector of target cell lysis by NK cells.
t
dResults
e
fSerine and Cysteine Protease Inhibitors, but Not
pCaspase Inhibitors, Block NK Cell-Mediated
pLysis of Target Cells
sTo confirm prior findings related to which protease
sclasses are required for cytotoxic lymphocyte-medi-
bated cell lysis, cytotoxicity assays were carried out in
othe presence of the caspase inhibitors Z-VAD-FMK and
SZ-DEVD-FMK, the serine protease inhibitor DCI (3,4-
qdichloroisocoumarin), and the cysteine protease inhibi-
stor E-64d (Figure 1). The NK cell line NK-92 and the NK-
asensitive target cell line K562 were used as a model
seffector and target cell pair, respectively. A combination
wof Z-VAD-FMK and Z-DEVD-FMK only had a minor ef-
sfect on cell lysis, in agreement with prior studies [17].
In contrast, DCI was found to be a potent inhibitor of
lysis, again in agreement with prior studies [18]. The S
acysteine protease inhibitor E-64d was also found to be
a potent inhibitor of lysis, possibly as a consequence G
aof cathepsin C inhibition [19]. These results verify find-
ings by other researchers and indicate that lysis of u
ztargets by NK cells is not dependent on caspases [17],
but is dependent on serine proteases [18, 20]. Addition- s
wally, these results indicate that lysis is also dependent
on cysteine proteases. While DCI is selective for serine g
pproteases, some of its observed effect may be due to
crossreactivity with cysteine proteases such as cal- t
3pain [21].
t
bThe Five Human Granzymes Exhibit Divergent
Extended Substrate Specificities t
nMore selective inhibitors, particularly members of the
granzyme family, would thus be useful for probing the p
srole of serine proteases in target cell lysis. Since
the activity of granzymes is highly dependent on ex- b
ltended and specific interactions with peptide ligands[
a
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BFigure 1. The Effect of Class-Specific Protease Inhibitors on NK
Cell-Mediated Lysis of Target Cells K
Lysis of K562 targets by NK-92 effectors is not inhibited by the t
caspase inhibitors Z-VAD-FMK and Z-DEVD-FMK, but it is inhibited g
by the cysteine protease inhibitor E-64d or the serine protease in- d
hibitor DCI.
z22, 23], tailored peptide-based inhibitors may provide
means to selectively target individual granzymes in
ysis assays. As a starting point for determining the fea-
ibility of such an approach, the extended substrate
pecificities of all human granzymes were compared by
sing combinatorial libraries of protease substrates.
he optimal P4-P3-P2-P1 (nomenclature for amino acid
ositions in substrates is Pn, Pn-1, ..., P2, P1 with am-
de bond hydrolysis occurring following P1) substrate
pecificities of the five human granzymes were deter-
ined to be IGNR for granzyme A, IEPD for granzyme
, PTSY for granzyme H, YRFK for granzyme K, and
VPL for granzyme M (Figure 2). These profiles indicate
hat the P4–P1 substrate specificities of the five human
ranzymes are quite distinct from one another. Such
ivergent specificities should allow preparation of gran-
yme-selective inhibitors.
Results obtained for granzymes A, B, and M are gen-
rally consistent with those obtained in previous studies
ith other positional scanning combinatorial libraries
23–25]. Although the optimal substrate specificity of
ranzyme A has previously been determined to be
ANR, the single substrate Ac-IGNR-ACC was found to
e approximately twice as sensitive as Ac-VANR-ACC
data not shown). Previous studies have demonstrated
hat granzyme H exhibits a preference for aromatic resi-
ues at P1 [26] and that granzyme K exhibits a prefer-
nce for lysine and arginine at P1 [27]. The library pro-
iles indicate that granzyme H, in fact, exhibits a strong
reference for tyrosine over phenylalanine and trypto-
han at this position, while granzyme K exhibits a
trong preference for lysine over arginine. The P4–P2
ubstrate specificities of these two granzymes have not
een previously characterized. The narrow specificity
f the five granzymes at P1 is particularly remarkable.
ince serine proteases derive much of the energy re-
uired for catalysis from binding P1, this property
hould aid in achieving selective chemical inhibition of
particular family member [28]. In instances in which
ome crossreactivity may be expected at P1, such as
ith granzymes A and K, distinct specificities at P4–P2
hould further contribute to selectivity.
ubstrate Specificity-Based Phosphonate Inhibitors
s Affinity Labels of Granzymes A and B
ranzymes A and B have a clear role in NK cell-medi-
ted cytotoxicity, but their role in induction of lysis is
nclear. To explore the contribution of the major gran-
ymes A and B to lysis of targets by NK cells, substrate
pecificity-based inhibitors of these two proteases
ere developed. These were designed to have the
eneral architecture of affinity labels containing a di-
henyl phosphonate electrophile, specificity elements
o impart selectivity, and a biotin tag (Figures 3A and
B). 4-amidinophenylglycine was used at the P1 posi-
ion of the granzyme A inhibitor in place of arginine
ased on precedent [28]. Although it has been reported
hat granzyme B is not inhibited by an acylated diphe-
yl phosphonate ester analog of aspartic acid [29],
eptide phosphonates based on the extended sub-
trate specificity of granzyme B have not previously
een described. Time-dependent inhibition and cova-
ent labeling of recombinant granzymes A and B indi-
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Recombinant granzymes A, B, H, and M were profiled at positions P4–P1 by using a completely diversified PS-SCL of ACC substrates.
Granzyme K was profiled at P4–P2 by using a PS-SCL of ACC substrates that is fixed as lysine at P1, and was profiled at P1 by using the
P1-Arg and P1-Lys wells of the completely diversified PS-SCL. The y axis represents relative activity, and the x axis represents the fixed P4,
P3, P2, or P1 amino acid (with norleucine represented by n). Activities for each enzyme are relative to the highest activity at each of the four
substrate positions.cate that bio-x-IGN(AmPhg)P-(OPh)2 and bio-x-IEPDP-
(OPh)2 function as irreversible inhibitors of their target
enzymes (Figures 3A and 3B). Activity assays of recom-
binant enzymes also indicate that both compounds are
selective for their target enzymes in the context of the
granzyme family (Table 1).
The Granzyme A- and B-Targeted Inhibitors Are
Selective in the Context of an NK Cell Proteome
To evaluate the selectivity of bio-x-IGN(AmPhg)P-(OPh)2
and bio-x-IEPDP-(OPh)2 in the context of relevant com-
plex biochemical mixtures, NK cell lysates were treated
with each inhibitor and analyzed by SDS-PAGE, fol-
lowed by avidin blotting. Treatment of NK-92 cell ly-
sates with each inhibitor led to selective labeling of a
single protein in a concentration-dependent manner
(Figures 4A and 4B). Labeling was activity based since,
in both cases, no labeling was detected when lysateswere preinactivated by denaturation with 2% SDS. Im-
munoprecipitation of human granzyme A or B from ly-
sates treated with inhibitors followed by avidin blotting
of immunoprecipitates demonstrates that the protein
labeled by bio-x-IGN(AmPhg)P-(OPh)2 is granzyme A
and the protein labeled by bio-x-IEPDP-(OPh)2 is gran-
zyme B (Figures 4C and 4D). Immunodepletion of ly-
sates removed the vast majority of biotinylated protein,
indicating that the inhibitors do not crossreact with pro-
teins of similar molecular weight to granzymes A and
B. Altogether, these labeling experiments indicate that
bio-x-IGN(AmPhg)P-(OPh)2 and bio-x-IEPDP-(OPh)2 are
remarkably selective for their target enzymes in the
context of an NK cell proteome.
Treatment of intact NK-92 cells with bio-x-IGN
(AmPhg)P-(OPh)2 or bio-x-IEPDP-(OPh)2 followed by
extensive washing of the cells also led to selective la-
beling of granzymes A and B (Figures 4E and 4F). At
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570Figure 3. The Phosphonates Bio-x-IGN(AmPhg)P-(OPh)2 and Bio-x-IEPDP-(OPh)2 Are Irreversible Inhibitors of Their Target Enzymes
(A) Bio-x-IGN(AmPhg)P-(OPh)2 inhibits the activity of recombinant granzyme A (1 M) with Suc-AAPR-pNA (1 mM) in a time-dependent manner
(dashed line, control; solid line, 10 M inhibitor). Incubation of recombinant granzyme A (1 ng) with bio-x-IGN(AmPhg)P-(OPh)2 (1 M) for 1
hr, followed by 6 hr of dialysis, SDS-PAGE analysis, and avidin blotting, indicates covalent labeling of the enzyme.
(B) Bio-x-IEPDP-(OPh)2 inhibits the activity of recombinant granzyme B (100 nM) with Ac-IEPD-pNA (1 mM) in a time-dependent manner
(dashed line, control; solid line, 10 M inhibitor). Incubation of recombinant granzyme B (1 ng) with bio-x-IEPDP-(OPh)2 (1 M) for 1 hr,
followed by 6 hr of dialysis, SDS-PAGE analysis, and avidin blotting, indicates covalent labeling of the enzyme.of lysates, and evaluation of inhibition by labeling with
b
a
s
Table 1. Inhibition of Human Granzymes by Bio-x-IGN(AmPhg)P- w
(OPh)2 and Bio-x-IEPDP-(OPh)2 w
kobs/[I] (M−1 s−1) f
pBio-x-IGN(AmPhg)P-
cGranzyme (OPh)2 Bio-x-IEPDP-(OPh)2
aA 2000 ± 200 NI
tB NIa 460 ± 35
H NI NI z
K NI NI c
M NI NI a
Inhibition constants represent the average, and errors represent the c
standard deviation from three separate experiments.
a NI indicates less than 10% inhibition after 4 hr of incubation with t
100 M inhibitor.
ihigher concentrations, the two inhibitors can access in- b
ztracellular granzymes A and B, and they are thus par-
tially cell permeable. Labeling in intact cells was also
found to be time dependent, further indicating that this
Ulabeling is not a result of a reaction between granzymes
aand inhibitors upon disruption of plasma membrane in-
Btegrity during preparation of lysates (data not shown).
LLack of labeling saturation in intact cells may be due to
Aa limit in cell permeability or to the fact that granzymes
tare maintained in a partially inactive state in the acidic
rgranules of NK cells (pH w5). The activity of serine pro-
ateases is optimal at close to neutral pH and decreases
hat lower pH [30]. Reactivity between phosphonate in-
thibitors and the catalytic serine residue of granzymes
cis thus expected to be decreased in the acidic environ-
Nment of intact granules. Treatment of intact NK cells
twith nonbiotinylated inhibitors, followed by preparation
Iiotinylated inhibitors also revealed only partial gran-
yme inactivation (data not shown).
se of Granzyme A- and B-Targeted Inhibitors
s Functional Probes Indicates that Granzyme
Is a Major Mediator of NK Cell-Mediated
ysis of Target Cells
lthough the amidine of bio-x-IGN(AmPhg)P-(OPh)2 and
he two acids of bio-x-IEPDP-(OPh)2 are likely to be det-
imental to cell permeability, labeling of granzymes A
nd B in intact NK cells demonstrates that the two in-
ibitors are partially cell permeable. To shed light on
he roles of granzymes A and B in the lysis of target
ells mediated by NK cells, cytotoxicity assays with
K-92 effectors and K562 targets were carried out in
he presence of bio-x-IGN(AmPhg)P-(OPh)2 and bio-x-
EPDP-(OPh)2. The granzyme B inhibitor blocked lysis
y more than 75%, while the granzyme A inhibitor had
far less pronounced effect (Figure 5A). The effect ob-
erved with bio-x-IEPDP-(OPh)2 in cytotoxicity assays
as found to be dependent on preincubation of cells
ith the inhibitor. This may be indicative of an active
orm of inhibitor uptake such as pinocytosis, which has
reviously been observed for other peptide-based
ompounds [31]. Studies were also conducted to ex-
mine the effect of both inhibitors on the processing of
he granzyme A protein substrate SET and the gran-
yme B protein substrate caspase-3, but technical diffi-
ulties related to low sensitivity in Western blots and
dventitious proteolysis during sample preparation pre-
luded clean interpretation of results.
To confirm that bio-x-IEPDP-(OPh)2 exerts its effect
hrough the blockade of a protein in effector cells, the
nhibitor was preincubated for 4 hr with effectors,
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571Figure 4. Selective Targeting of Granzyme A
by Bio-x-IGN(AmPhg)P-(OPh)2 and Gran-
zyme B by Bio-x-IEPDP-(OPh)2 in NK Cell Ly-
sates and Intact NK Cells
(A) Concentration-dependent and activity-
based labeling of a single protein in NK-92
cell lysates by bio-x-IGN(AmPhg)P-(OPh)2.
(B) Concentration-dependent and activity-
based labeling of a single protein in NK-92
cell lysates by bio-x-IEPDP-(OPh)2.
(C) Immunoprecipitation of NK-92 cell ly-
sates indicates that the protein labeled by
bio-x-IGN(AmPhg)P-(OPh)2 is granzyme A.
(D) Immunoprecipitation of NK-92 cell ly-
sates indicated that the protein labeled by
bio-x-IEPDP-(OPh)2 is granzyme B.
(E) Concentration-dependent labeling of gran-
zyme A in intact NK-92 cells by bio-x-IG-
N(AmPhg)P-(OPh)2.
(F) Concentration-dependent labeling of gran-
zyme B in intact NK-92 cells by bio-x-
IEPDP-(OPh)2.targets, or both prior to the start of killing assays. Such
longer incubations with targets were not compatible
with time-resolved fluorimetric cytotoxicity assays be-
cause of prohibitively high background TDA release.
Cell mixtures were instead analyzed by flow cytometry
for propidium iodide incorporation by using APC-con-
jugated anti-CD56 to distinguish effectors from tar-
gets (Figure 5B). In the absence of bio-x-IEPDP-(OPh)2,
31.4% of targets were found to be propidium iodide
positive. When only targets were preincubated with
bio-x-IEPDP-(OPh)2, 29.6% of targets were found to be
propidium iodide positive. When only effectors were
preincubated with bio-x-IEPDP-(OPh)2, 21.6% of targets
were found to be propidium iodide positive. Finally,
when both targets and effectors were preincubated
with bio-x-IEPDP-(OPh)2, 17.0% of targets were found
to be propidium iodide positive. Inhibition of lysis by
bio-x-IEPDP-(OPh)2 is thus more dependent on preincu-
bation with effectors than with targets. These results
indicate that bio-x-IEPDP-(OPh)2 acts on a protein
found in effector cells and also validate the effect ob-
served in the time-resolved fluorimetric cytotoxicity
assay (Figure 5A). The magnitude of inhibition by
bio-x-IEPDP-(OPh)2 in the cytometry assay is an under-
estimate because of a consistent background of w5%
propidium iodide-positive targets and because deadcells that have disintegrated to debris are not ac-
counted for.
Levels of Granzymes A and B in NK Cell Lines
Correlate with Cytotoxicity
Labeling with both inhibitors was observed in lysates
of the NK cell lines NK-92 and NKL, but not in lysates
of the control cell lines K562 and Daudi (Figure 6A). The
activity-based profiles of granzymes A and B across
cell lines are generally consistent with Western blots of
the same lysates for granzymes A and B (Figure 6A).
Interestingly, densitometric quantitation of these avidin
and Western blots reveals that, on a per cell basis, very
low levels of granzyme B are found in the cell line NKL
(Figure 6B). Even with high sample loading (2 × 106 cells
per lane in Figure 6 versus 5 × 104 cells per lane in
Figure 4), granzyme B is not easily detected in NKL ly-
sates with the commonly used anti-human granzyme B
monoclonal antibody 2C5. Activity-based profiling with
bio-x-IEPDP-(OPh)2 appears to be a more sensitive
method for detection of granzyme B, allowing for a
comparison between granzyme B levels in NK-92 and
NKL cells. Labeling with inhibitors indicates that while
30% less granzyme A is found in NKL cells than in NK-
92 cells, 85% less granzyme B is found in NKL cells
than in NK-92 cells. In agreement with the effect ob-
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Figure 5. Granzyme B Functions as a Major Effector of NK Cell-
Mediated Lysis of Target Cells
g
(A) Bio-x-IEPDP-(OPh)2, but not bio-x-IGN(AmPhg)P-(OPh)2, inhibits (
lysis of K562 targets by NK-92 effectors. Effectors were preincu-
d
bated for 4 hr, and targets were preincubated for 1 hr alone, with
100 M bio-x-IGN(AmPhg)P-(OPh)2, or with 100 M bio-x-IEPDP-
(OPh)2 prior to mixing at an effector to target cell ratio of four. Inhib- citors were also present during the cytotoxicity assay at the same
nconcentrations. Data represent the average, and error bars repre-
asent the standard deviation from four separate experiments.
(B) The effect of bio-x-IEPDP-(OPh)2 is dependent on preincubation i
with effectors, but it is not dependent on preincubation with s
targets. 100 M bio-x-IEPDP-(OPh)2 was preincubated for 4 hr with c
effectors, targets, or both prior to mixing at an effector to target [cell ratio of four. Following incubation, cell mixtures were analyzed
pby flow cytometry for propidium iodide incorporation by using
iAPC-conjugated anti-CD56 to distinguish effectors from targets.
b
sigure 6. Levels of Granzymes A and B in Different Cell Lines Are
onsistent with Granzyme B Serving a More Prominent Role in
arget Cell Lysis than Granzyme A
A) Activity-based profiling of granzyme A with 100 M bio-x-IGN
AmPhg)P-(OPh)2, granzyme B with 100 M bio-x-IEPDP-(OPh)2,
nd Western blotting of granzymes A and B across different cell
ines.
B) Densitometric quantitation of activity-based profiles and West-
rn blots reveals markedly lower levels of granzyme B, but not
ranzyme A, in the cell line NKL relative to the cell line NK-92.
C) Lower levels of granzyme B in the cell line NKL correlate with
ecreased cytotoxicity relative to the cell line NK-92.wserved with bio-x-IEPDP-(OPh)2 in the cell lysis assays,
the decreased granzyme B levels in NKL cells correlate t
Awith the lower lytic potential exhibited by this cell line
(Figure 6C). w
b
sDiscussion
o
Genetic studies of granzymes A and B have greatly
contributed to the understanding of these two prote- t
rases as effectors of cell-based immunity. The increased
susceptibility to viral infection exhibited by mice lack- t
cing either one or both of these granzymes is especiallyompelling evidence for their important role in immu-
ity [8]. Although knowledge gained from granzyme A
nd B knockout mice exemplifies how traditional genet-
cs continues to be an immensely powerful tool for
tudy of protein function, the utility and advantages of
hemical genetics are gaining increasing recognition
16]. In particular, use of chemical inhibitors to block
rotein function offers a level of temporal control that
s unparalleled, even in comparison to gene silencing
y RNA interference. A common drawback of using
mall molecules as functional probes is crossreactivity
ith unintended targets, particularly when the intended
arget is highly homologous to a set of other proteins.
n elegant and generalizable solution to this problem,
hich combines synthetic chemistry and genetics, has
een applied to the study of protein kinases [32]. A
imilarly generalizable approach has yet to be devel-
ped for proteases.
The inhibitors described herein were developed with
he goal of establishing chemical probes to further cur-
ent understanding of granzymes A and B. As a means
o account for potential inhibitor crossreactivity, these
ompounds were designed as tagged affinity labels.
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selectivity in the context of complex mixtures. The
granzyme A inhibitor bio-x-IGN(AmPhg)P-(OPh)2 and
the granzyme B inhibitor bio-x-IEPDP-(OPh)2 were both
found to be remarkably selective based on labeling in
cell lysates and intact cells. Selectivity among all five
human granzymes was also verified by activity. Much
like peptide acyloxymethylketone and fluoromethylke-
tone inhibitors of caspases [33], the granzyme A and B
inhibitors described in this work demonstrate how tai-
loring of specificity determinants and choice of an appro-
priate electrophile facilitate preparation of extremely se-
lective peptide-based inhibitors of proteases. Whereas
electrophiles such as chloromethylketones and alde-
hydes react with active site nucleophiles of a variety of
enzymes, fluorophosphate inhibitors are selective for ser-
ine hydrolases [34], and peptidyl diphenyl phosphonate
esters exhibit an additional level of selectivity for serine
proteases [35]. The selectivity of bio-x-IGN(AmPhg)P-
(OPh)2 and bio-x-IEPDP-(OPh)2 in a cellular context
makes them ideal functional probes for studies of cyto-
toxic lymphocyte function.
Experiments with lymphocytes from knockout mice,
and those with reconstituted systems of purified per-
forin and granzymes, are generally in agreement re-
garding the roles of granzymes A and B in DNA damage
[13, 15, 36]. In contrast, results regarding the role of
these proteases in lysis are conflicting [13–15]. Target
cell lysis was originally attributed to the formation of
large pores in the plasma membrane of target cells by
perforin polymers. But this model was updated follow-
ing the discovery that these pores are not large enough
to allow passage of the macromolecular complex be-
tween granzymes and the proteoglycan serglycin [37,
38]. The current model of granule exocytosis involves
uptake of granzyme-serglycin complexes and perforin
by target cells into endosomes. Through an unknown
mechanism, perforin then acts as an endosomolytic
agent to allow escape of the granzymes into the cyto-
plasm [37, 38]. Although perforin is absolutely required
for lysis of target cells by cytotoxic lymphocytes [39],
it is unlikely to be the sole effector of lysis under physi-
ological conditions. The first among several indications
that serine proteases play a role in this process came
from experiments in which general serine protease in-
hibitors such as DCI and DFP (diisopropyl phospho-
fluoridate) were observed to block the cytolytic activity
of cytotoxic lymphocytes [18, 20].
Use of bio-x-IGN(AmPhg)P-(OPh)2 and bio-x-IEPDP-
(OPh)2 in cytotoxicity assays has herein allowed dissec-
tion of the contribution of granzymes A and B to lysis
of target cells by NK cells. The granzyme B inhibitor
bio-x-IEPDP-(OPh)2 potently inhibited lysis of K562
target cells by NK-92 effector cells, while the granzyme
A inhibitor bio-x-IGN(AmPhg)P-(OPh)2 had a less pro-
nounced effect. Lack of a pronounced effect on lysis in
the presence of bio-x-IGN(AmPhg)P-(OPh)2 may be a
result of inefficient granzyme A inhibition in the cell-
based assay, possibly due to poor cell permeability. Al-
ternatively, lack of a pronounced effect may be an indi-
cation that granzyme A is only a minor effector of lysis.
The latter scenario appears more likely given that both
bio-x-IGN(AmPhg)P-(OPh)2 and bio-x-IEPDP-(OPh)2 are
efficient inhibitors of their target enzymes in vitro, thatlabeling indicates that both access their target en-
zymes with approximately the same efficiency in intact
NK cells, and that the charged and thus presumably
sparingly cell-permeable bio-x-IEPDP-(OPh)2 is active
in the same assay. More importantly, a greater than
75% blockade of lysis by bio-x-IEPDP-(OPh)2 in a stan-
dard assay indicates that, even if the remaining 25%
lysis is completely attributable to granzyme A, gran-
zyme B functions as a major effector of target cell lysis,
and granzyme A likely functions as a relatively minor
effector in the same process.
This finding stands in contrast to experiments with
cytotoxic lymphocytes from knockout mice, which sup-
port a role for neither granzyme in lysis [13], and experi-
ments with reconstituted systems, which support a role
for both granzymes in lysis [14, 15]. A potential recon-
ciliation for results from all three methods of study is
that: 1) no marked effect in lysis is observed for either
granzyme in genetic studies because of compensation
by other granzymes; 2) a marked effect is observed for
both granzymes in reconstituted systems because the
concentrations and/or mode of delivery of granzymes
and perforin are not physiological; 3) a marked effect is
observed for granzyme B, but not for granzyme A, in
pharmacological studies because temporal control cir-
cumvents compensation, and because no alterations
are made to the concentrations and mode of delivery
of granzymes and perforin. Studies are underway to de-
termine whether granzyme B functions as a major me-
diator of lysis in systems other than the model of NK-
92 effectors and K562 targets used in this work.
A role for granzyme B in lysis has also subsequently
been verified by using a potent and selective reversible
inhibitor of granzyme B obtained from Merck [40]. This
compound exhibits an inhibitory effect similar to that of
bio-x-IEPDP-(OPh)2 in our lysis assays (data not shown).
A role for granzyme B in lysis is also consistent with
levels of this protease in the cell lines NK-92 and NKL.
Far higher effector to target cell ratios are necessary to
achieve maximal lysis with the NKL line than with the
NK-92 line [41, 42]. Although similar granzyme A levels
were found in both cell lines, significantly lower gran-
zyme B levels were found in the NKL line. While small-
molecule inhibitors of granzyme A that are selective
in vitro have been reported to be active in cell lysis as-
says [43, 44], their selectivity in a cellular context has
not been verified. It is therefore possible that the ob-
served effect is a result of crossreactivity with an un-
known target or granzyme B. Many of these com-
pounds are based on an isocoumarin scaffold, which is
known to inhibit not only serine proteases but also
some cysteine proteases and proteasome activities
[21]. Possible crossreactivity of these compounds with
cysteine proteases is particularly relevant since use of
E-64d demonstrates that a blockade of cysteine prote-
ase activity also affects lysis.
Cytotoxic lymphocyte-mediated death undoubtedly
has an apoptotic component, manifested in hallmarks
such as caspase activation, oligonucleosomal DNA frag-
mentation, and mitochondrial depolarization. On the
other hand, rapid lysis of target cells clearly indicates
that cytotoxic lymphocyte-mediated death has a necrotic
component as well. This necrosis is not likely to be a
secondary effect of apoptosis since it occurs indepen-
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cmore rapidly than secondary necrosis [45]. Because
granzyme B activates caspases and cleaves several c
known caspase substrates, it has generally been thought
of as a proapoptotic effector of death. The work pre- i
psented herein directly implicates granzyme B in death
pathways culminating in lysis, and therefore indicates f
ethat granzyme B is a pronecrotic as well as proapo-
ptotic effector of death. Although the molecular mecha- c
bnism of lysis in cytotoxic lymphocyte-mediated death
is not well understood, it is tempting to speculate that a
zplasma membrane disruption is a downstream result
of granzyme B-mediated processing of specific protein a
gsubstrates. It has been demonstrated that cleavage of
plasma membrane Ca2+ pumps by caspases in apo- o
tptotic neurons leads to secondary necrosis [46].
Whether granzyme B alters the osmotic balance of g
ptarget cells through a similar mechanism remains to be
determined. The granzyme B inhibitor bio-x-IEPDP-
p(OPh)2 should serve as a useful tool for dissection of
pronecrotic pathways involving granzyme B and for i
kidentification of macromolecular substrates in these
pathways. a
tThe granule exocytosis pathway has been linked to
autoimmune disorders such as allograft rejection [3, 4], d
erheumatoid arthritis [5], diabetes [6], and graft-versus-
host disease [7]. Some of the granzymes may represent p
upotential therapeutic targets for these disorders. In par-
ticular, an interesting molecular link exists between i
tgranzyme B and autoimmunity since several protein
substrates of granzyme B are known autoantigens [47]. i
The finding that granzyme B is a key mediator of target
cell lysis sheds new light on its potential role in the E
progression of autoimmune disease. Uptake of apo-
Rptotic cells by phagocytes, which occurs under condi-
Utions of normal tissue turnover, generally results in the
tinduction of tolerance to self. In contrast, uptake of
t
necrotic cells by phagocytes, which occurs following f
cytotoxic lymphocyte-mediated lysis of virally infected a
fcells, results in T cell activation and induction of an in-
Sflammatory response [48]. As a major mediator of cell
wlysis by cytotoxic lymphocytes, granzyme B functions
anot only as an effector of death, but also as a key prop-
(
agator of the immune response. In this sense, chemical L
blockade of granzyme B can be predicted to result in
an anti-inflammatory effect that attenuates autoimmu- H
nity. It is noteworthy that the granule exocytosis path- G
way is linked to several of the autoimmune disorders R
pfor which the proinflammatory cytokine TNF-α is a ther-
capeutic target [49]. The work presented herein indicates
Sthat granzyme B may be a viable alternate point of in-
ctervention for treatment of these disorders.
c
p
cSignificance
The substrate specificity-based diphenyl phospho- P
Hnates prepared herein for granzymes A and B were
pfound to be remarkably selective for their target en-
tzymes, even in the context of complex biochemical
mmixtures. As affinity labels, these inhibitors function
g
as sensitive activity-based probes of granzymes A X
and B. More significantly, use of these inhibitors in L
bcell-based assays has yielded new, to our knowledge,nsight into the function of granzymes A and B that
ould not be easily deduced from prior genetic or bio-
hemical experiments.
Results regarding the roles of granzymes A and B
n the lysis of target cells mediated by cytotoxic lym-
hocytes are conflicting. It is possible that this con-
lict is a result of compensation in the case of genetic
xperiments and low physiological relevance in the
ase of biochemical experiments. Development of
io-x-IGN(AmPhg)P-(OPh)2 and bio-x-IEPDP-(OPh)2 has
llowed for a selective chemical blockade of gran-
ymes A and B in cell-based assays as an alternative
pproach for probing the function of these two major
ranzymes. This pharmacological approach has dem-
nstrated that granzyme B functions as a major effec-
or of NK cell-mediated lysis of target cells, while
ranzyme A likely plays a secondary role in this
rocess.
This is an interesting finding because it directly im-
licates granzyme B in pronecrotic pathways of death
n addition to the proapoptotic pathways it is already
nown to trigger through the caspases. Importantly
nd in agreement with prior studies, NK cell-mediated
arget cell lysis was found to be caspase indepen-
ent, indicating that bio-x-IEPDP-(OPh)2 does not ex-
rt its effect through caspase inhibition. Because
hagocytic uptake of virally infected cells that have
ndergone necrotic death induces a proinflammatory
mmune response, it is likely that granzyme B func-
ions as a key propagator as well as a mediator of the
mmune response following pathogen infection.
xperimental Procedures
eagents
nless otherwise specified, all solvents and chemicals were ob-
ained from Sigma-Aldrich. Amino acids and resins used for pep-
ide synthesis were obtained from Novabiochem. DCI was obtained
rom Roche. Z-VAD(OMe)-FMK, Z-D(OMe)E(OMe)VD(OMe)-FMK,
nd recombinant human granzyme K from E. coli were obtained
rom Calbiochem. E-64d, Suc-AAPR-pNA, Ac-IEPD-pNA, Suc-FLF-
Bzl, and Z-K-SBzl were obtained from Bachem. Ac-KVPL-ACC
as prepared as previously described [23]. The cell lines NK-92
nd K562 were obtained from the American Type Culture Collection
ATCC). The cell lines NKL and Daudi were generous gifts from Dr.
ewis Lanier (University of California, San Francisco).
eterologous Expression and Purification of Human
ranzymes A, B, H, and M
ecombinant human granzymes A and M from P. pastoris were pre-
ared and purified as previously described [23, 24]. The cDNA en-
oding mature human granzyme B was a generous gift from Dr.
andra Waugh Ruggles (Catalyst Biosciences), and the cDNA en-
oding mature human granzyme H was amplified from I.M.A.G.E.
lone 5936395. Recombinant human granzymes B and H were pre-
ared and purified in a manner analogous to that reported for re-
ombinant human granzymes A and M.
ositional Scanning Synthetic Combinatorial Libraries
uman granzymes A, B, H, and M were profiled by using a com-
letely diversified PS-SCL (positional scanning synthetic combina-
orial library) of tetrapeptide ACC (7-amino-4-carbamoylmethylcou-
arin) substrates (Y. Choe and C.S.C., unpublished data). Human
ranzyme K was profiled by using the Ac-XXXR-ACC and Ac-
XXK-ACC wells of the completely diversified PS-SCL, and a P1-
ys PS-SCL of tetrapeptide ACC substrates [50]. Screening of li-
raries was carried out as previously described [50].
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Detailed synthetic procedures are included as Supplemental Data
available online. In general, the diphenyl phosphonate ester analog
of 4-amidinophenylglycine, H-(AmPhg)P-(OPh)2, was prepared essen-
tially as previously described [51] and was purified by HPLC. The
peptide biotinyl-Ahx-Ile-Gly-Asn(Trt)-OH was prepared on 2-chlo-
rotrityl chloride resin by using standard fluorenylmethoxycarbonyl
chemistry and was purified by HPLC. Phosphonate and peptide
were coupled by using PyBOP and diisopropylethylamine in di-
methylformamide, and the product biotinyl-Ahx-Ile-Gly-Asn(Trt)-
(AmPhg)P-(OPh)2 was obtained following HPLC purification. The tri-
tyl protecting group was removed in 95% trifluoroacetic acid, 2.5%
water, and 2.5% triisopropylsilane. The final product, biotinyl-Ahx-
Ile-Gly-Asn-(AmPhg)P-(OPh)2, was obtained following HPLC purifi-
cation and was characterized by mass spectrometry. Mass calcd
for C48H65N10O10PS: 1004.4. MALDI-TOF m/z found: 1005.7 (M+H)+.
Synthesis of Bio-x-IEPDP-(OPh)2
Detailed synthetic procedures are included as Supplemental Data.
In general, the side chain-protected diphenyl phosphonate ester
analog of aspartic acid, H-Asp(ONb)P-(OPh)2, was prepared by
using p-nitrobenzyl formylacetate in the condensation reaction de-
veloped by Oleksyszyn et al. [52] and was purified by HPLC. The
peptide biotinyl-Ahx-Ile-Glu(OBzl)-Pro-OH was prepared on 2-chlo-
rotrityl chloride resin by using standard fluorenylmethoxycarbonyl
chemistry and was purified by HPLC. Phosphonate and peptide
were coupled by using PyBOP and diisopropylethylamine in di-
methylformamide, and the product biotinyl-Ahx-Ile-Glu(OBzl)-Pro-
Asp(ONb)P-(OPh)2 was obtained following HPLC purification. Ben-
zyl and p-nitrobenzyl protecting groups were removed by catalytic
hydrogenation in ethanol. The final product, biotinyl-Ahx-Ile-Glu-
Pro-AspP-(OPh)2, was obtained following HPLC purification and
was characterized by mass spectrometry. Mass calcd for C47H66
N7O13PS: 999.4. MALDI-TOF m/z found: 999.7 (M+H)+.
Inhibitor Kinetics
The pseudo second-order rate constants kobs/[I] for inhibition of
recombinant granzyme A (100 nM) by bio-x-IGN(AmPhg)P-(OPh)2
(1 M) and recombinant granzyme B (1 M) by bio-x-IEPDP-(OPh)2
(10 M) were determined according to the method of Kitz and Wil-
son [53]. Enzymes and inhibitors were incubated at 25°C in the
same assay buffer as that used for PS-SCL studies, and they were
diluted 100-fold into assay buffer at fixed intervals. The remaining
enzymatic activity was determined by using Z-K-SBzl (1 mM) for
granzyme A and Ac-IEPD-pNA (1 mM) for granzyme B. Crossreac-
tivity of both inhibitors among granzymes was determined by incu-
bation of each granzyme (1 M) with either inhibitor (100 M) at
25°C in assay buffer for 4 hr. The remaining enzymatic activity was
determined following 100-fold dilutions into assay buffer by using
Z-K-SBzl (1 mM) for granzymes A and K, Ac-IEPD-pNA (1 mM) for
granzyme B, Suc-FLF-SBzl (100 M) for granzyme H, and Ac-
KVPL-ACC (1 mM) for granzyme M. Final DMSO concentrations
in assays never exceeded 2%. Hydrolysis of SBzl substrates was
monitored spectrophotometrically at 405 in the presence of DTNB
(5,5#-dithio-bis(2-nitrobenzoic acid)) (100 M). Hydrolysis of Ac-
IEPD-pNA was monitored spectrophotometrically at 405 nm. Hy-
drolysis of Ac-KVPL-ACC was monitored as described for library
assays.
Affinity Labeling of Cell Lysates
Bio-x-IGN(AmPhg)P-(OPh)2 or bio-x-IEPDP-(OPh)2 from DMSO
stocks was added to 25 l 106 cell/ml or 107 cell/ml lysates of
NK-92, NKL, K562, or Daudi cells prepared in PBST (phosphate-
buffered saline with 0.1% Triton X-100). Final inhibitor concentra-
tions were as indicated in the Results section. Final DMSO concen-
trations were 1%. Lysates were incubated with inhibitors for 1 hr at
25°C. 12% SDS (5 l) was added to lysates either before incubation
for preinactivated samples or following incubation to quench reac-
tions. Following the addition of 6× gel loading buffer (6 l) to the
resulting lysates, samples were boiled for 2 min, and sample vol-
umes corresponding to 5 × 104 cells/well for inhibitor titrations or
to 2 × 106 cells/well for activity profiling across cell lines were ana-
lyzed by SDS-PAGE and avidin blotting as described below.Affinity Labeling of Intact NK Cells
Bio-x-IGN(AmPhg)P-(OPh)2 or bio-x-IEPDP-(OPh)2 from DMSO
stocks was added to 25 l 107 intact NK-92 cells/ml in RPMI 1640
containing 10% fetal bovine serum. Final inhibitor concentrations
were as indicated in the Results section. Final DMSO concentra-
tions were 1%. Cells were incubated with inhibitors for 4 hr at 37°C,
washed with PBS (5 × 500 l), and lysed in PBST (250 l). Following
the addition of 6× gel loading buffer (10 l) to 50 l of the resulting
lysates, samples were boiled for 2 min, and sample volumes corre-
sponding to 1 × 105 cells/well were analyzed by SDS-PAGE and
avidin blotting as described below.
Immunoprecipitation
Bio-x-IGN(AmPhg)P-(OPh)2 or bio-x-IEPDP-(OPh)2 from DMSO
stocks was added to 25 l 107 cell/ml NK-92 cell lysates prepared
in PBST. Final inhibitor concentrations were 100 M, and final
DMSO concentrations were 1%. Cell lysates were incubated with
inhibitors for 1 hr at 25°C and were diluted into PBS (215 l) con-
taining 2.5 g anti-human granzyme A monoclonal antibody CB9
(BD Biosciences) or anti-human granzyme B monoclonal antibody
GB11 (Serotec). Diluted lysates were incubated with antibodies for
1 hr at 25°C, and a 50% slurry of protein G sepharose (Amersham
Pharmacia) in PBST (20 l) was added. Lysates were incubated
with sepharose beads for 1 hr at 25°C, and beads were separated
from supernatant and washed with PBS (3 × 500 l). 12% SDS (5 l)
and 6× gel loading buffer (6 l) were added to 25 l of the original
supernatant. PBS (50 l), 12% SDS (5 l), and 6× gel loading buffer
(6 l) were added to the beads. Samples were boiled for 2 min, and
sample volumes corresponding to 1 × 105 cells/well for supernatant
or 60 l for beads were then analyzed by SDS-PAGE and avidin
blotting as described below.
Avidin Blot Analysis
Protein samples were separated by SDS-PAGE and transferred to
a nitrocellulose membrane. The membrane was blocked in TBST
(Tris-buffered saline with 0.1% Triton X-100) containing 5% nonfat
dry milk, washed with TBST, incubated in a solution of VECTASTAIN
ABC Standard (Vector Laboratories) biotin detection reagent in
TBST according to manufacturer’s instructions, and washed with
TBST. Avidin bound protein bands were then detected by enhanced
chemiluminescence (Amersham Biosciences).
Immunoblot Analysis
Protein samples were separated by SDS-PAGE and transferred to
a nitrocellulose membrane (Schleicher & Schuell). The membrane
was blocked in TBST containing 5% nonfat dry milk, incubated
in a solution of anti-human granzyme A monoclonal antibody GA6
(Serotec) (1 g/ml) or a solution of anti-human granzyme B mono-
clonal antibody 2C5 (BD Biosciences) (1 g/ml) in TBST containing
5% nonfat dry milk, washed with TBST, incubated in a 1:10,000
dilution of horseradish peroxidase-conjugated secondary antibody
(Bio-Rad) in TBST containing 5% nonfat dry milk, and washed
again with TBST. Antibody bound protein bands were then de-
tected by enhanced chemiluminescence (Amersham Biosciences).
Cell-Mediated Cytotoxicity Assay
The lysis assay employed was a time-resolved fluorimetric assay
based on preloading of target cells with BATDA (Perkin Elmer), an
acetoxymethyl ester of the Eu3+ fluorescence-enhancing ligand
TDA, and quantitation of EuTDA chelate fluorescence following ad-
dition of cell media to a solution of Eu3+. Results obtained by using
this assay are similar to those obtained by using the more tradi-
tional radioactive 51Cr release assay [54]. K562 cells were incu-
bated at 106 cells/ml in RPMI 1640 containing 10% fetal bovine
serum with BATDA (20–80 M) for 2 hr at 37°C. These targets were
then washed five times with 1 ml PBS. Assays were conducted in
round-bottom 96-well plates with 5000 targets per well. The num-
ber of effectors corresponded to the effector to target cell ratios
indicated in the Results section. A total volume of 200 l RPMI
1640 containing 10% fetal bovine serum was used per well. Targets
and effectors were mixed, and plates were centrifuged and incu-
bated for 4 hr at 37°C. Maximum release was determined by the
addition of 0.05% Triton X-100 to wells containing 5000 targets 30
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576min prior to the end of the assay. Spontaneous release was deter-
mined by using media from wells containing 5000 targets. Media
from each well (10 l) were added to 96-well plates containing 50
M EuCl3·6H2O in 300 mM acetate (pH 4.0) (100 l). Following agi-
tation of plates for 5 min, time-resolved fluorescence was mea-
sured by using an excitation wavelength of 289 nm and an emission
wavelength of 616 nm. Percent specific lysis was calculated as
100 × (experimental release − spontaneous release)/(maximum re-
lease − spontaneous release). Each experimental, spontaneous, or
maximum release value used in this calculation was an average of
values from triplicate wells.
Inhibitors in Cell-Mediated Cytotoxicity Assays
Efficacy of inhibitors in the cytotoxicity assay described above was
evaluated by preincubating effectors with each inhibitor in RPMI
1640 containing 10% fetal bovine serum (100 l) for 4 hr at 37°C,
preincubating targets (after BATDA preloading) with each inhibitor
in RPMI 1640 containing 10% fetal bovine serum (100 l) for 1 hr
at 37°C, and then mixing both to start the cytotoxicity assay as
described above. DCI was preincubated with effectors for 1 hr in-
stead of 4. Final inhibitor concentrations were 100 M. Final DMSO
concentrations were 1%. Inhibitors were not toxic at the concentra-
tions used in assays, as evaluated by trypan blue exclusion. The
inhibitors bio-x-IGN(AmPhg)P-(OPh)2 and bio-x-IEPDP-(OPh)2 were
used at a maximal concentration of 100 M since concentrations
higher than 200 M were found to be toxic.
1Flow Cytometry
NK-92 cells and K562 cells at 2 × 106 cells/ml in RPMI 1640 con-
taining 10% fetal bovine serum (50 l in both cases) were incu-
1
bated at 37°C for 4 hr alone or in the presence of bio-x-IEPDP-
(OPh)2 (100 M). Final DMSO concentrations were 1% in all cases. 1
Following inhibitor preincubations, NK-92 cells (40 l) were mixed
with K562 cells (10 l) and incubated at 37°C for another 2 hr. PBS
(425 l), APC-conjugated anti-CD56 antibody (BD Pharmingen) (20
l), and 10 g/ml propidium iodide (Molecular Probes) were then
added to the cell mixture. Cells were incubated in the dark at 25°C
1
for 30 min, and samples were analyzed on a BD FACSCalibur flow
cytometry system.
Supplemental Data 1
Supplemental Data containing detailed synthetic procedures for
the preparation of bio-x-IGN(AmPhg)P-(OPh)2 and bio-x-IEPDP-
(OPh)2 are available at http://www.chembiol.com/cgi/content/full/
12/5/567/DC1/. 1
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